You are not logged in.

Gene expression signature: a powerful approach for drug discovery in diabetes

Sithara, Smithamol, Crowley, Tamsyn M., Walder, Ken and Aston-Mourney, Kathryn 2017, Gene expression signature: a powerful approach for drug discovery in diabetes, Journal of endocrinology, vol. 232, no. 2, pp. R131-R139, doi: 10.1530/JOE-16-0515.

Attached Files
Name Description MIMEType Size Downloads

Title Gene expression signature: a powerful approach for drug discovery in diabetes
Author(s) Sithara, Smithamol
Crowley, Tamsyn M.
Walder, Ken
Aston-Mourney, Kathryn
Journal name Journal of endocrinology
Volume number 232
Issue number 2
Start page R131
End page R139
Total pages 9
Publisher BioScientifica
Place of publication Bristol, Eng.
Publication date 2017-02-01
ISSN 1479-6805
Keyword(s) complex disease
drug discovery
gene expression signature
type 2 diabetes
Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
GENOME-WIDE ASSOCIATION
BETA-CELL PROLIFERATION
DIPEPTIDYL PEPTIDASE-4 INHIBITORS
IMPAIRED GLUCOSE-TOLERANCE
BREAST-CANCER
DOUBLE-BLIND
CYCLOPHOSPHAMIDE CHEMOTHERAPY
INSULIN SENSITIVITY
SUSCEPTIBILITY LOCI
ACUTE-PANCREATITIS
Summary Type 2 diabetes (T2D) is increasing in prevalence at an alarming rate around the world. Much effort has gone into the discovery and design of antidiabetic drugs; however, those already available are unable to combat the underlying causes of the disease and instead only moderate the symptoms. The reason for this is that T2D is a complex disease, and attempts to target one biological pathway are insufficient to combat the full extent of the disease. Additionally, the underlying pathophysiology of this disease is yet to be fully elucidated making it difficult to design drugs that target the mechanisms involved. Therefore, the approach of designing new drugs aimed at a specific molecular target is not optimal and a more expansive, unbiased approach is required. In this review, we will look at the current state of diabetes treatments and how these target the disease symptoms but are unable to combat the underlying causes. We will also review how the technique of gene expression signatures (GESs) has been used successfully for other complex diseases and how this may be applied as a powerful tool for the discovery of new drugs for T2D.
Language eng
DOI 10.1530/JOE-16-0515
Field of Research 111502 Clinical Pharmacology and Therapeutics
1103 Clinical Sciences
0707 Veterinary Sciences
0702 Animal Production
Socio Economic Objective 920106 Endocrine Organs and Diseases (excl. Diabetes)
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2017, Society for Endocrinology
Persistent URL http://hdl.handle.net/10536/DRO/DU:30091596

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 59 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Wed, 01 Mar 2017, 15:27:27 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.